Belgium
Montis Biosciences, founded in 2020 and headquartered in Belgium, emerges as a pioneer in the biotechnology sector, addressing unmet needs in health and wellness. Positioned as a preclinical-stage biopharmaceutical innovator, the company is set to transform the treatment landscape for inflammation-driven autoimmune and neurodegenerative diseases.
Their flagship program, MB01, innovatively targets the multifaceted roles of C1q, a crucial mediator in neuroinflammatory conditions. By going beyond traditional pathways, Montis leverages novel anti-C1q antibodies, presenting a potential breakthrough for these diseases. The company also leads the charge with MB02, targeting CD93 in lung squamous cell carcinoma.
With a recent $9.06M investment, backed by heavyweights like Polaris Partners, ALSA Ventures, and Pfizer Ventures, Montis is poised for growth. The robust support from its investor syndicate coupled with experienced leadership positions it for success as it eyes two Phase 1 trials by the first half of 2026.
